Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

Barbara Mora; Elisa Rumi; Paola Guglielmelli; Daniela Barraco; Margherita Maffioli; Alessandro Rambaldi; Marianna Caramella; Rami Komrokji; Jason Gotlib; Jean Jacques Kiladjian; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T. Silver; Giulia Benevolo; Francesco Albano; Chiara Cavalloni; Daniela Pietra; Tiziano Barbui; Giada Rotunno; Mario Cazzola; Alessandro Maria Vannucchi; Toni Giorgino; Francesco Passamonti

doi:10.1002/cam4.2107

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

Barbara Mora, Elisa Rumi, Paola Guglielmelli, Daniela Barraco, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami Komrokji, Jason Gotlib, Jean Jacques Kiladjian, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Giulia Benevolo, Francesco Albano, Chiara Cavalloni, Daniela PietraTiziano Barbui, Giada Rotunno, Mario Cazzola, Alessandro Maria Vannucchi, Toni Giorgino, Francesco Passamonti

Risultato della ricerca: Contributo in rivista › Articolo in rivista

5 Citazioni (Scopus)

Abstract

Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patientyears. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.

Lingua originale	English
pagine (da-a)	4089-4092
Numero di pagine	4
Rivista	Cancer Medicine
Volume	8
DOI	https://doi.org/10.1002/cam4.2107
Stato di pubblicazione	Pubblicato - 2019

Keywords

JAK inhibitors
Second malignancy
Secondary myelofibrosis

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1002/cam4.2107

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Mora, B., Rumi, E., Guglielmelli, P., Barraco, D., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, V., Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., ... Passamonti, F. (2019). Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine, 8, 4089-4092. https://doi.org/10.1002/cam4.2107

@article{f71e92b8e15047c6bb4da2e182d40dc2,

title = "Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients",

abstract = "Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patientyears. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.",

keywords = "JAK inhibitors, Second malignancy, Secondary myelofibrosis, JAK inhibitors, Second malignancy, Secondary myelofibrosis",

author = "Barbara Mora and Elisa Rumi and Paola Guglielmelli and Daniela Barraco and Margherita Maffioli and Alessandro Rambaldi and Marianna Caramella and Rami Komrokji and Jason Gotlib and Kiladjian, {Jean Jacques} and Francisco Cervantes and Timothy Devos and Francesca Palandri and {De Stefano}, Valerio and Marco Ruggeri and Silver, {Richard T.} and Giulia Benevolo and Francesco Albano and Chiara Cavalloni and Daniela Pietra and Tiziano Barbui and Giada Rotunno and Mario Cazzola and Vannucchi, {Alessandro Maria} and Toni Giorgino and Francesco Passamonti",

year = "2019",

doi = "10.1002/cam4.2107",

language = "English",

volume = "8",

pages = "4089--4092",

journal = "Cancer Medicine",

issn = "2045-7634",

publisher = "Oxford : Blackwell Publishing",

}

Mora, B, Rumi, E, Guglielmelli, P, Barraco, D, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, JJ, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, RT, Benevolo, G, Albano, F, Cavalloni, C, Pietra, D, Barbui, T, Rotunno, G, Cazzola, M, Vannucchi, AM, Giorgino, T & Passamonti, F 2019, 'Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients', Cancer Medicine, vol. 8, pagg. 4089-4092. https://doi.org/10.1002/cam4.2107

TY - JOUR

T1 - Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

AU - Mora, Barbara

AU - Rumi, Elisa

AU - Guglielmelli, Paola

AU - Barraco, Daniela

AU - Maffioli, Margherita

AU - Rambaldi, Alessandro

AU - Caramella, Marianna

AU - Komrokji, Rami

AU - Gotlib, Jason

AU - Kiladjian, Jean Jacques

AU - Cervantes, Francisco

AU - Devos, Timothy

AU - Palandri, Francesca

AU - De Stefano, Valerio

AU - Ruggeri, Marco

AU - Silver, Richard T.

AU - Benevolo, Giulia

AU - Albano, Francesco

AU - Cavalloni, Chiara

AU - Pietra, Daniela

AU - Barbui, Tiziano

AU - Rotunno, Giada

AU - Cazzola, Mario

AU - Vannucchi, Alessandro Maria

AU - Giorgino, Toni

AU - Passamonti, Francesco

PY - 2019

Y1 - 2019

N2 - Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patientyears. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.

AB - Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patientyears. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.

KW - JAK inhibitors

KW - Second malignancy

KW - Secondary myelofibrosis

KW - JAK inhibitors

KW - Second malignancy

KW - Secondary myelofibrosis

UR - http://hdl.handle.net/10807/152286

U2 - 10.1002/cam4.2107

DO - 10.1002/cam4.2107

M3 - Article

SN - 2045-7634

VL - 8

SP - 4089

EP - 4092

JO - Cancer Medicine

JF - Cancer Medicine

ER -

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo